Kate Mostoller
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Pharmacological Effects and Toxicity Studies, Bone health and osteoporosis research, Neuroscience and Neuropharmacology Research, Epilepsy research and treatment
Most-Cited Works
- → A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment(2020)52 cited
- → Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622(2018)38 cited
- → Odanacatib, a Selective Cathepsin K Inhibitor, Demonstrates Comparable Pharmacodynamics and Pharmacokinetics in Older Men and Postmenopausal Women(2013)32 cited
- → Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics(2021)22 cited
- → Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs – midazolam and odanacatib(2014)22 cited
- → Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK ‐1293 insulin glargine and originator insulin glargine ( L antus) in subjects with type 1 diabetes and healthy subjects(2017)20 cited
- → Early-stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients(2013)14 cited
- → Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery(2020)3 cited
- → Issue Information(2019)1 cited
- → Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects(2019)